Women referred for colposcopy with mild and moderate dyskaryosis and found to have only minor cervical abnormalities were screened for oncogenic human papilloma virus (HPV) types. The natural development of these abnormalities in 42 HPV-positive women was assessed by cytology and colposcopy at 6-mon
Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study
✍ Scribed by Véronique Dalstein; Didier Riethmuller; Jean-Luc Prétet; Karine Le Bail Carval; Jean-Loup Sautière; Jean-Pierre Carbillet; Bernadette Kantelip; Jean-Patrick Schaal; Christiane Mougin
- Book ID
- 102271501
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 110 KB
- Volume
- 106
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Oncogenic HPV types are the major cause of worldwide cervical cancer, but only a small proportion of infected women will develop high‐grade cervical intraepithelial neoplasia or cancer (CIN2/3+). We performed a prospective study including 781 women with normal, atypical squamous cells of undetermined significance (ASCUS) or low‐grade squamous intraepithelial lesion (LGSIL) cytology, and infected or not by high‐risk (HR) HPV tested by Hybrid Capture II. Women were followed up every 6 months for a median period of 22 months. Among the HR‐HPV‐positive women at entry, more than half cleared their virus in 7.5 months; the clearance rate was greater for low viral loads than for high loads and also was higher in women with an initial ASCUS/LGSIL smear than in women with normal cytology. The incidence of cytologic abnormalities strongly depended on baseline viral load and HR‐HPV persistence. Maintenance of cytologic abnormalities was associated with the outcome of HR‐HPV status (negative
📜 SIMILAR VOLUMES
## Abstract To test the reliability of the Hybrid Capture II (HC‐II) assay detecting 13 high‐risk human papillomavirus (HR‐HPV) types for the screening of cervical lesions, we monitored by cytology, HR‐HPV testing, colposcopy and biopsy, 3,091 women with normal smears at the first entry. Our primar